PubAg

Main content area

Rotavirus hospitalizations among children <5 years of age—Tajikistan, 2013–2014

Author:
Nazurdinov, Anvar B., Azizov, Zafarjon A., Tishkova, Farida, Turkov, Sohibnazar M., Daniels, Danni S., Leshem, Eyal
Source:
Vaccine 2018 v.36 no.51 pp. 7794-7797
ISSN:
0264-410X
Subject:
Rotavirus, burden of disease, children, enzyme-linked immunosorbent assay, feces, gastroenteritis, genotype, genotyping, immunization, intravenous injection, monitoring, patients, polymerase chain reaction, vaccines, Tajikistan
Abstract:
In January 2015, Tajikistan introduced the monovalent rotavirus vaccine into the national immunization program. Our objective was to estimate pre-vaccine burden of rotavirus-associated hospitalizations in children <5 years of age in Tajikistan.During January 2013–December 2014, active surveillance for acute gastroenteritis (AGE)-associated hospitalizations in children <5 years of age was conducted by sentinel surveillance site staff. Patients’ demographic and clinical data were summarized and a stool sample was collected. An Enzyme Linked Immunosorbent Assay was used for diagnosis of rotavirus infection and subset of the specimens was sent for polymerase chain reaction (PCR) genotyping.Of 2860 eligible children enrolled and tested, 1207 (42%) were positive for rotavirus. An increase in the number and proportion of rotavirus cases attributed to rotavirus season, with positivity rates >40%, was annually observed during June–September.The median age of rotavirus patients was 9 months and 939/1207 (78%) rotavirus patients were aged 6–23 months. Most (1097/1203; 91%) rotavirus patients were treated with intravenous fluids. G1P[8] was the predominant genotype during both years of surveillance, accounting for 133/222 (60%) of genotyped cases.Rotavirus is a major cause of hospitalization due to severe AGE in children <5 years of age in Tajikistan, accounting for >40% of cases. Continued, enhanced rotavirus surveillance may allow documentation of changes in rotavirus disease burden following vaccine introduction and assessment of vaccine effectiveness.
Agid:
6235714